Nevertheless, only a few clinical trials have already taken place which have shown that the treatment with dronabinol, a dual CB1/CB2 agonist, leads to a little but significant weight gain in anorexia rodent models and humans with anorexia nervosa, potentially due to a reduction in the urge to be physically active [376,377]. Here, CNR1 is linked to anorexia nervosa.